Keytruda and AFM13 to be investigated in Hodgkin lymphoma
25 January 2016 | By Victoria White
The purpose of the study is to establish a dosing regimen for this combination therapy and assess its safety and efficacy...
List view / Grid view
News
Empower your research with Tecan’s Spark® 20M multimode reader
25 January 2016 | By Tecan
Tecan has launched the Spark® 20M multimode microplate reader, offering tailor-made solutions to suit virtually any drug discovery or advanced life science research application...
Ixchelsis announces positive Phase 2a results for IX-01
25 January 2016 | By Victoria White
IX-01 is an oral oxytocin receptor antagonist being developed for the treatment of premature ejaculation...
Shire resubmits NDA for lifitegrast to the FDA
25 January 2016 | By Victoria White
Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA in October last year...
Broad Institute Genomic Services offers genomic insight into Ninlaro
25 January 2016 | By Victoria White
Ninlaro (ixazomib) was recently approved by the FDA, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma...
Opdivo + Yervoy regimen receives expanded FDA approval
25 January 2016 | By Victoria White
The FDA has approved Opdivo (nivolumab) + Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma...
Vectibix and best supportive care improves OS in mCRC
25 January 2016 | By Victoria White
Amgen has announced results from a study of Vectibix and best supportive care in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC)...
New analyses of second-line treatment following AG in pancreatic cancer
25 January 2016 | By Victoria White
Celgene has announced results from multiple analyses evaluating second-line treatments following Abraxane and gemcitabine (AG) in metastatic pancreatic cancer patients.
SCLC treatment market value to rise to $2.29b by 2024, says GlobalData
22 January 2016 | By Victoria White
GlobalData states that the impressive growth will primarily be driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents...
EC approves Type II variation for Takeda’s Adcetris
22 January 2016 | By Victoria White
The EC has approved the Type II variation for Adcetris to include data on the retreatment of adult patients with R/R Hodgkin lymphoma or R/R sALCL who previously responded to Adcetris and who later relapse....
Benefit-risk profile of ambroxol and bromhexine medicines confirmed by EC
22 January 2016 | By Victoria White
The decision includes an update of the product information of all ambroxol and bromhexine containing products to include the rare risk of hypersensitivity reactions and a Precaution and Warning regarding severe cutaneous adverse reactions...
FDA approves new Kyprolis combination therapy in multiple myeloma
22 January 2016 | By Victoria White
The FDA has approved the supplemental New Drug Application (sNDA) of Amgen’s Kyprolis (carfilzomib) for injection in combination with dexamethasone or with lenalidomide plus dexamethasone...
NICE says ‘yes’ to Opdivo (nivolumab) in melanoma
22 January 2016 | By Victoria White
NICE recommends that nivolumab is made available on the NHS as a treatment option for patients with advanced (unresectable or metastatic) melanoma...
Allergan reports positive results from trials of Viberzi in IBS-D
21 January 2016 | By Victoria White
In the Phase III trials, significantly more patients treated with Viberzi experienced improvements in diarrhoea and abdominal pain, as compared with placebo...
Pulmonary arterial hypertension treatment market to experience modest growth
21 January 2016 | By Victoria White
The pulmonary arterial hypertension treatment market will grow from $3.45 billion in 2014 to $4.75 billion by 2024, according to research and consulting firm GlobalData...
